# BioCryst Turns First Profit

> BioCryst becomes profitable with Orladeyo and plans rare disease acquisitions.
- Title: BioCryst Turns First Profit · Yahoo Finance | Shortify
- Summary: BioCryst becomes profitable with Orladeyo and plans rare disease acquisitions. BioCryst Pharmaceuticals achieved its first profit from Orladeyo and plans to…
- Keywords: biocryst, orladeyo, rare disease drugs, astria therapeutics, navenibart, hereditary angioedema, nasdaq, bcrx, business, finance, Turns, First
- Source: Yahoo Finance — https://finance.yahoo.com/healthcare/articles/biocryst-bcrx-turns-first-profit-160606434.html
- Published: 2026-09-17T16:06:06+00:00
- Read time: 1 min
- Topics: biocryst, orladeyo, rare disease drugs, astria therapeutics, navenibart, hereditary angioedema, nasdaq, bcrx, business, finance
## BioCryst Turns First Profit
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported consistent profitability on August 28, 2026, from its hereditary angioedema drug Orladeyo.
## Orladeyo Generates $645m Sales
Orladeyo is projected to bring up to $645 million in 2026 sales, providing BioCryst with a self-funded growth engine.
## Acquired Astria Therapeutics
BioCryst acquired Astria Therapeutics in January 2026, adding navenibart, a late-stage hereditary angioedema candidate.
## Navenibart Trial Data Expected 2027
Navenibart completed enrollment in its pivotal trial in June 2026, with data expected in 2027 if the drug succeeds.
## Sold European Business for $250m
BioCryst sold its European Orladeyo business to Neopharmed Gentili for $250 million upfront in 2025.
## Licensed European Rights for $70m
BioCryst licensed European commercialization rights for navenibart to a Neopharmed affiliate for $70 million upfront, up to $275 million in milestones, and 18-30% royalties.
## Financial Risks Remain
BioCryst still faces $822 million in obligations and negative shareholders' equity despite profitability, limiting acquisition flexibility.
## Key takeaway

BioCryst Pharmaceuticals achieved its first profit from Orladeyo and plans to acquire rare disease treatments using cash from the drug.